Author: Vogel, Victor G

Source: Expert Review of Anticancer Therapy, Volume 9, Number 1, January 2009 , pp. 51-60(10)

Publisher: Expert Reviews

Abstract:

In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years. There were an equal number of cases of invasive breast cancer in women assigned to tamoxifen and raloxifene. There were fewer cases of noninvasive breast cancer in the tamoxifen group than in the raloxifene group (risk ratio [RR]: 1.40; 95% confidence interval [CI]: 0.98-2.02). There were more cases of uterine cancer with tamoxifen than with raloxifene (RR: 0.62; 95% CI: 0.35-1.08). Thromboembolic events occurred less often in the raloxifene group (RR: 0.70; 95% CI: 0.54-0.91) and there were fewer cataracts and cataract surgeries in the women taking raloxifene (RR: 0.79; 95% CI: 0.68-0.92). The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer. The risk of other cancers, fractures, ischemic heart disease and stroke is similar for both drugs.

Keywords: breast cancer risk reduction; chemoprevention; primary prevention; raloxifene; selective estrogen receptor modulator; tamoxifen

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737140.9.1.51

Affiliations: 1: Professor of Medicine and Epidemiology, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine; and, Co-Director, Biochemoprevention Prevention, University of Pittsburgh Cancer Institute, Magee-Womens

Publication date: 2009-01-01

More about this publication?

• Expert Review of Anticancer Therapy provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Pharmacology
• By this author: Vogel, Victor G

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers